As a major STAT5 target gene, its expression is strongly increased in a range of myeloproliferative disorders where STAT5 is activated, including BCR/ABL-induced CML (169) and JAK2 V617F-induced disease (170). The gene discussed is STAT5B; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.